Real‐World Effectiveness and Cost‐Differential of Intranasal Esketamine Versus Intramuscular Ketamine
Psychiatric Research and Clinical Practice July 2, 2026 Kush V. Bhatt, Tara Austin, Danny Alam et al.
Objective This study evaluated whether intramuscular (IM) ketamine is non‐inferior to intranasal (IN) esketamine for treatment‐resistant depression (TRD) and assessed differences in safety and healthcare costs. Methods In a retrospective, observational sequential cohort at the VA San Diego, 179 Veterans with TRD received eight treatments of either IN esketamine ( n = 89) or IM ketamine ( n =...